Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F L Yao

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Biochemical and Biophysical Research Communications|December 16, 1987
Observation of a possible pause mutant in the total synthesis of T4 lysozymeS A Narang, J Phipps, F L Yao, et al.
Biologicals : Journal of the International Association of Biological Standardization|July 14, 1999
Modifications of HIV-1 retrovirus-like particles to enhance safety and immunogenicityR H Persson, S X Cao, G Cates, et al.
Protein Engineering|December 1, 1987
Hierarchical strategy for protein folding and design: synthesis and expression of T4 lysozyme gene and two putative folding mutantsS A Narang, F L Yao, J J Michniewicz, et al.
Nucleic Acids Research|October 25, 1989
A unique sequence of the Bordetella pertussis toxin operonS M Loosmore, J D Cunningham, W R Bradley, et al.
Virology|May 18, 1999
Engineering of noninfectious HIV-1-like particles containing mutant gp41 glycoproteins as vaccine candidates that allow vaccinees to be distinguished from HIV-1 infecteesB Rovinski, G A Dekaban, S X Cao, et al.
AIDS Research and Human Retroviruses|October 1, 1995
Induction of HIV type 1 neutralizing and env-CD4 blocking antibodies by immunization with genetically engineered HIV type 1-like particles containing unprocessed gp160 glycoproteinsB Rovinski, L Rodrigues, S X Cao, et al.
International Journal of Epidemiology|June 1, 1992
An efficacy trial of a mammalian cell-derived recombinant DNA hepatitis B vaccine in infants born to mothers positive for HBsAg, in Shanghai, ChinaM L Halliday, L Y Kang, J G Rankin, et al.
Infection and Immunity|November 1, 1990
Engineering of genetically detoxified pertussis toxin analogs for development of a recombinant whooping cough vaccineS M Loosmore, G R Zealey, H A Boux, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Biochemical and Biophysical Research Communications|December 16, 1987
Observation of a possible pause mutant in the total synthesis of T4 lysozymeS A Narang, J Phipps, F L Yao, et al.
Biologicals : Journal of the International Association of Biological Standardization|July 14, 1999
Modifications of HIV-1 retrovirus-like particles to enhance safety and immunogenicityR H Persson, S X Cao, G Cates, et al.
Protein Engineering|December 1, 1987
Hierarchical strategy for protein folding and design: synthesis and expression of T4 lysozyme gene and two putative folding mutantsS A Narang, F L Yao, J J Michniewicz, et al.
Nucleic Acids Research|October 25, 1989
A unique sequence of the Bordetella pertussis toxin operonS M Loosmore, J D Cunningham, W R Bradley, et al.
Virology|May 18, 1999
Engineering of noninfectious HIV-1-like particles containing mutant gp41 glycoproteins as vaccine candidates that allow vaccinees to be distinguished from HIV-1 infecteesB Rovinski, G A Dekaban, S X Cao, et al.
AIDS Research and Human Retroviruses|October 1, 1995
Induction of HIV type 1 neutralizing and env-CD4 blocking antibodies by immunization with genetically engineered HIV type 1-like particles containing unprocessed gp160 glycoproteinsB Rovinski, L Rodrigues, S X Cao, et al.
International Journal of Epidemiology|June 1, 1992
An efficacy trial of a mammalian cell-derived recombinant DNA hepatitis B vaccine in infants born to mothers positive for HBsAg, in Shanghai, ChinaM L Halliday, L Y Kang, J G Rankin, et al.
Infection and Immunity|November 1, 1990
Engineering of genetically detoxified pertussis toxin analogs for development of a recombinant whooping cough vaccineS M Loosmore, G R Zealey, H A Boux, et al.
Pageof 2